Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,473 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Incidence and risk factors for venous thromboembolism in gynecological cancer: the GOTIC-VTE trial.
Takahashi Y, Fujiwara H, Yamamoto K, Yamaguchi S, Nagao S, Takano M, Miyamoto M, Hasegawa K, Miwa M, Yasuoka T, Yamashita S, Hirakawa T, Nagai T, Hamada Y, Uno M, Mori-Uchino M, Ohwada M, Mitsuhashi A, Satoh T, Fujiwara K, Suzuki M; GOTIC-VTE Trial Investigators. Takahashi Y, et al. Among authors: hasegawa k. J Thromb Thrombolysis. 2024 Nov 27. doi: 10.1007/s11239-024-03055-1. Online ahead of print. J Thromb Thrombolysis. 2024. PMID: 39602066
Prevention of symptomatic pulmonary embolism for gynecologic malignancies with preoperative asymptomatic venous thromboembolism: GOTIC-VTE trial.
Takahashi Y, Fujiwara H, Yamamoto K, Takano M, Miyamoto M, Hasegawa K, Miwa M, Satoh T, Itagaki H, Hirakawa T, Mori-Uchino M, Nagai T, Hamada Y, Yamashita S, Yano H, Kato T, Fujiwara K, Suzuki M; GOTIC-VTE Trial Investigators. Takahashi Y, et al. Among authors: hasegawa k. J Gynecol Oncol. 2024 Jul;35(4):e37. doi: 10.3802/jgo.2024.35.e37. Epub 2024 Jan 1. J Gynecol Oncol. 2024. PMID: 38178702 Free PMC article. Clinical Trial.
Intraperitoneal Carboplatin for Ovarian Cancer - A Phase 2/3 Trial.
Nagao S, Fujiwara K, Yamamoto K, Tanabe H, Okamoto A, Takehara K, Saito M, Fujiwara H, Tan DSP, Yamaguchi S, Adachi S, Kikuchi A, Hirasawa T, Yokoi T, Nagai T, Sato T, Kamiura S, Fujishita A, Loong WW, Chan K, Syks P, Olawaye A, Ryu SY, Shigeta H, Kondo E, Yokoyama Y, Matsumoto T, Hasegawa K, Enomoto T. Nagao S, et al. Among authors: hasegawa k. NEJM Evid. 2023 May;2(5):EVIDoa2200225. doi: 10.1056/EVIDoa2200225. Epub 2023 Apr 21. NEJM Evid. 2023. PMID: 38320049 Clinical Trial.
Re-administration of platinum-based chemotherapy for recurrent endometrial cancer: an ancillary analysis of the SGSG-012/GOTIC-004/Intergroup study.
Nagao S, Nishio S, Takehara K, Sato S, Satoh T, Shimada M, Yamaguchi S, Tanabe H, Takano M, Horie K, Takei Y, Imai Y, Hibino Y, Hasegawa K, Takekuma M, Nakamura K, Takano H, Fujiwara K, Masuyama H. Nagao S, et al. Among authors: hasegawa k. Int J Clin Oncol. 2024 Oct;29(10):1594-1601. doi: 10.1007/s10147-024-02585-1. Epub 2024 Jul 13. Int J Clin Oncol. 2024. PMID: 39001945 Free PMC article.
A phase 2 study of intraperitoneal carboplatin plus intravenous dose-dense paclitaxel in front-line treatment of suboptimal residual ovarian cancer.
Hasegawa K, Shimada M, Takeuchi S, Fujiwara H, Imai Y, Iwasa N, Wada S, Eguchi H, Oishi T, Sugiyama T, Suzuki M, Nishiyama M, Fujiwara K. Hasegawa K, et al. Br J Cancer. 2020 Mar;122(6):766-770. doi: 10.1038/s41416-020-0734-9. Epub 2020 Jan 31. Br J Cancer. 2020. PMID: 32001833 Free PMC article. Clinical Trial.
Feasibility study of combination chemotherapy with paclitaxel, doxorubicin and cisplatin without prophylactic granulocyte colony-stimulating factor injection for intermediate-to-high risk or recurrent endometrial cancer.
Nagao S, Nishikawa T, Hanaoka T, Kurosaki A, Iwasa N, Hasegawa K, Fujiwara K. Nagao S, et al. Among authors: hasegawa k. Jpn J Clin Oncol. 2014 Nov;44(11):1040-4. doi: 10.1093/jjco/hyu124. Epub 2014 Sep 2. Jpn J Clin Oncol. 2014. PMID: 25183770 Clinical Trial.
Prediction of response to promising first-line chemotherapy in ovarian cancer patients with residual peritoneal tumors: practical biomarkers and robust multiplex models.
Kawabata-Iwakawa R, Iwasa N, Satoh K, Colinge J, Shimada M, Takeuchi S, Fujiwara H, Eguchi H, Oishi T, Sugiyama T, Suzuki M, Hasegawa K, Fujiwara K, Nishiyama M. Kawabata-Iwakawa R, et al. Among authors: hasegawa k. Int J Clin Oncol. 2024 Sep;29(9):1334-1346. doi: 10.1007/s10147-024-02552-w. Epub 2024 May 20. Int J Clin Oncol. 2024. PMID: 38767719
4,473 results